Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|29|3224-3228

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.29, 2011-10, pp. : 3224-3228

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of an anti-CD200 antibody for prolonging the survival of allografts: a patent evaluation of WO2012106634A1

By Rygiel Tomasz P   Luijk Bart   Meyaard Linde  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 3, 2013-03 ,pp. : 389-392

Informa Healthcare

Access to resources Recommend Favorite

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

By Hassan Sufia Butt   Sørensen Jesper Freddie   Olsen Barbara Nicola   Pedersen Anders Elm  

Immunopharmacology and Immunotoxicology, Vol. 36, Iss. 2, 2014-04 ,pp. : 96-104

Informa Healthcare

Access to resources Recommend Favorite

Construction of an Anti-IL-1&bgr; scfv and TNFRI Fusion Protein and Its Therapeutic Effect on RA Mice Model

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 12, 2013-11 ,pp. : 1048-1061

Bentham Science Publishers

Access to resources Recommend Favorite

GAD-alum: balanced results in new-onset type 1 diabetes

By  

Inpharma, Vol. 1, Iss. 1660, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The Molecular Targets of Anti-HIV-1 Triterpenes, An Update

By  

Medicinal Chemistry Reviews - Online, Vol. 2, Iss. 5, 2005-10 ,pp. : 423-427

Bentham Science Publishers

Access to resources Recommend Favorite